A Study of S-1 in Combination With Gemcitabine as First-Line Treatment in Patients With Advanced Biliary Tract Cancer

Trial Profile

A Study of S-1 in Combination With Gemcitabine as First-Line Treatment in Patients With Advanced Biliary Tract Cancer

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 16 Jul 2017

At a glance

  • Drugs Gimeracil/oteracil/tegafur (Primary) ; Gemcitabine
  • Indications Biliary cancer
  • Focus Therapeutic Use
  • Sponsors TTY Biopharm
  • Most Recent Events

    • 05 Jul 2017 Planned End Date changed from 1 Jun 2017 to 1 Aug 2017.
    • 06 Feb 2017 Status changed from recruiting to active, no longer recruiting.
    • 11 Jan 2016 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top